The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter phase 2 trial of ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with combination chemotherapy with anti-EGFR antibody: JACCRO CC-16.
 
Masato Nakamura
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Akihito Tsuji
Speakers' Bureau - Bristol-Myers Squibb Corporation; Chugai Pharma; Lilly Japan; Merck Serono; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Yoshihiro Okita
No Relationships to Disclose
 
Toshihiko Matsumoto
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
 
Tamotsu Sagawa
No Relationships to Disclose
 
Takanori Watanabe
No Relationships to Disclose
 
Kozo Kataoka
Speakers' Bureau - Lilly Japan; Merck
 
Dai Manaka
No Relationships to Disclose
 
Kazuhiro Shiraishi
No Relationships to Disclose
 
Naoya Akazawa
No Relationships to Disclose
 
Tatsuya Okuno
No Relationships to Disclose
 
Takaya Shimura
No Relationships to Disclose
 
Manabu Shiozawa
No Relationships to Disclose
 
Shingo Noura
No Relationships to Disclose
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Merck; MSD K.K
Research Funding - Chugai Pharma; Lilly Japan; Nihonkayaku; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda
 
Yasuki Akiyama
Speakers' Bureau - Takeda
 
Hirofumi Ota
Honoraria - Daiichi Sankyo; Lilly Japan
 
Masahiro Takeuchi
No Relationships to Disclose
 
Wataru Ichikawa
Honoraria - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Merck Serono; Nihonkayaku; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Masashi Fujii
Travel, Accommodations, Expenses - Japan Clinical Cancer Research Organization